Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.

about

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.

Item

http://www.wikidata.org/entity/Q55041688

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Spotlight on olaparib in the t ...... elopment and place in therapy.

@en

Spotlight on olaparib in the t ...... elopment and place in therapy.

@nl

type

Item

label

Spotlight on olaparib in the t ...... elopment and place in therapy.

@en

Spotlight on olaparib in the t ...... elopment and place in therapy.

@nl

prefLabel

Spotlight on olaparib in the t ...... elopment and place in therapy.

@en

Spotlight on olaparib in the t ...... elopment and place in therapy.

@nl

P1476

Spotlight on olaparib in the t ...... elopment and place in therapy.

@en

P2093

Elisa Tripodi

http://www.w3.org/2001/XMLSchema#string

Francesco Raspagliesi

http://www.w3.org/2001/XMLSchema#string

Giuseppa Maltese

http://www.w3.org/2001/XMLSchema#string

Ilaria Sabatucci

http://www.w3.org/2001/XMLSchema#string

Stefano Lepori

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Novel inhibitors of poly(ADP-ribose) synthetase

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

Integrated genomic analyses of ovarian carcinoma

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Cancer statistics, 2014

P304

1501-1509

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2147/DDDT.S124447

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Domenica Lorusso

Giorgio Bogani

P5008

ScienceSource

P577

2018-05-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29881257

http://www.w3.org/2001/XMLSchema#string

P921

P932

5983012

http://www.w3.org/2001/XMLSchema#string